1 Executive Summary: In Vitro Diagnostics Market 2008-2023
2 Introduction to In-Vitro Diagnostics
2.1 The Continuing Success of the Healthcare Industries is Dependent upon Important Drivers and Restraints
2.1.1 Drivers of Sales in Global Healthcare Markets from 2008-2023
2.1.2 The Global Healthcare Markets Will Also Face Considerable Restraints Throughout the Foreseeable Future
2.2 What are In Vitro Diagnostic (IVD) Tests?
2.2.1 In Vitro Diagnostics are Medical Assays
2.2.2 Diagnosis and Disease Management
2.2.3 Screening of Populations and Risk Factors
2.2.4 How are In Vitro Diagnostic Technologies Regulated by the FDA?
2.2.5 Point-of-Care Testing
2.3 Advanced Diagnostics and Personalised Medicine
2.3.1 Polymerase Chain Reaction (PCR)
2.3.2 Need for Better Targeted Medicine to Suit Patient Sub-Populations
2.3.3 The Dawn of Pharmacogenomic Medicine
2.3.4 Completion of the Human Genome Project Has Been a Major Driver of Molecular Diagnostics and Personalised Medicine
2.3.5 Personalised Medicine Will Rely Heavily Upon Theranostics – Cooperation Between Diagnostics and Pharmaceutical Sectors
2.4 The Human Genome Project Has Provided Important Scope for Pharmaceutical and Diagnostics Industries
2.4.1 Human Genome Project Marked Start of Genomic Era
2.4.2 Harnessing the Genomic Data is a Major Challenge for Science and Healthcare Industries for Many Years to Come
2.5 Biomarkers and Theranostics
2.5.1 Greater Understanding of Molecular Basis of Disease is Vital
2.5.2 Biomarkers Are Important for Determining Efficacy and Safety
2.5.3 The Scope of Biomarkers is Vast – The Search Will Intensify in the Years Ahead
2.6 Pharmacogenomics is Increasingly Relevant to Pharmaceutical Development
2.6.1 Genetic Variation and Response to Therapy
2.6.2 Molecular Technologies in Medical Science will Strongly Influence the Pharmaceutical and Molecular Diagnostics Sectors
2.6.3 The Number of Companies and Strategic Alliances is Increasing
2.7 Proteomics Constitutes the "Next Step" After Genomics
2.7.1 Applied Study of Protein Structure and Form is Important to Medical Developments
2.7.2 Elucidating the Relationship Between Genes and Proteins
2.8 Personalised Medicine Supported By Theranostics Could Supersede the Existing Blockbuster Model, With Sustainable Revenue Flows Continuing
2.8.1 Personalised Medicine Could Bring Significant Financial Gains for Diagnostics and Pharmaceutical Industries
2.8.2 Far-Sighted Pharma Companies are Looking Beyond the Present Technological and Commercial Challenges
2.9 Companies Are Gradually Changing Their Strategic Focus to Overcome Challenges in the Worldwide Healthcare Market
2.9.1 Product Life Cycle Management (PLM)
2.9.2 R&D Strategy is Crucial to Success
2.9.3 The Blockbuster “Model” Will Yield to More Segmented Product Development
2.10 Healthcare Stakeholders Can Benefit from Changes to Regulatory Processes
2.10.1 “Live” Licensing and “In-Life” Testing – The Way Forward?
2.10.2 Limited Approval Leading to Testing for Expanded License
2.10.3 Proposed Framework Could Bring Benefits to Patients While Aiding Drug Developers
2.11 There is an Expanding Market for In Vitro Diagnostics – Especially Molecular Diagnostics
2.11.1 Sales Potential for Increasingly Effective Diagnostic Agents is High
2.11.2 Personalised Medicine Will Not Necessarily Mark the End of High Revenues
2.11.3 The Demands of Treating Patient Sub-Populations Now a Prime Commercial Driver in Diagnostics and Pharmaceutical Industries
3 The World In Vitro Diagnostics Market 2013-2023
3.1 Significant Sales Growth Predicted for the Overall Global In Vitro Diagnostics Market from 2007 to 2023
3.1.1 IVD Market Led by Metabolism, Oncology and Infection Market Segments
3.1.2 Sales in Oncology Will Be Driven by Need for Early Detection and Determination of Efficacy
3.1.3 Metabolism and Oncology to Increase Market Shares in Overall IVD Market
3.2 Global IVD Market Breakdown by Principal Technology
3.2.1 High Growth for Nucleic Acid Testing
3.2.2 Nucleic Acid Testing is The Fastest Growing Segment of the Global Diagnostics Market
3.2.3 The Developing Role of Molecular Technologies in Clinical Diagnostics
3.2.4 Shift to Molecular Diagnostics with Drive for Personalised Medicine
3.2.5 Limitations to Revenue Growth in the IVD Market
3.2.6 Rise in Market for Diabetes Testing Products
3.2.7 Emerging Technologies Growing in Prominence from 2007 to 2023
3.2.8 Increasingly Important Role of IVD Technologies in Drug Discovery
3.2.9 Genetic Screening Sector has Great Potential as Emerging Technology and Market
3.2.10 Growth Restrained by Pricing Ceilings and Downward Pressures on Healthcare Spending
3.3 Fast-Growing Technologies in the Nucleic Acid Market Segment
3.3.1 The Nucleic Acid Segment Contains Some of the Brightest Hopes for the IVD Market
3.3.2 DNA Probes Segment Will Show High Growth from 2007-2023
3.3.3 Nucleic Acid Testing in a Point-of-Care (POC) Setting
3.3.4 Impact of Molecular Medicine Provides a Significant Boost for Molecular Diagnostics
3.3.5 Importance of PCR-Based Technology
3.3.6 Clinical Genetic Testing Still Emergent
3.4 Personalised Medicine Will Become More Prominent in Healthcare With Theranostics Benefiting as a Result
3.4.1 Personalised Medicine in its Infancy but Still a Great Hope for Advancement of IVD Sector
3.4.2 Theranostics Aids Matching of Patients with Treatments – Helping to Optimise Efficacy and Safety
3.4.3 Greater Use of IVD Tests Could Significantly Reduce Adverse Drug Reactions and Cut Mortality Rates Associated With Drug Treatment
3.5 The Completion of the Human Genome Project Has Been a Major Driver of Molecular Diagnostics
3.5.1 Human Genome Sequencing has Made Matching of Therapy to Genetics and Phenotype a Possibility
3.5.2 High Gains for Developers and Marketers of Targeted Therapies and Supporting IVD Tests
3.6 Biomarker Technology is Still Emerging – But the Technological and Commercial Potential Remains Very Significant
3.6.1 Biomarker Use Increasingly Prevalent - but Long Way to Go Still
3.6.2 Biomarkers Key to Growth of IVD Market from Present Onwards
3.7 Protein Chip Technologies Gaining in Importance
3.7.1 Protein Chip Technologies in Molecular Diagnostics
3.7.2 What are the Advantages and Limitations of Protein Chip Technologies in Clinical Diagnostics?
3.7.3 Diagnostic Applications of Protein Chip Technologies
3.7.4 Which System Will Lead the Way for Diagnostic Protein Chip Technologies?
3.7.5 Cancer Diagnostics - The Key Field in the Future of Protein Chip Assays
4 Issues Affecting the Molecular Diagnostics Market
4.1 A SWOT Analysis for In Vitro Diagnostics
4.2 Diagnostics Companies Will Continue To Expand Their Presence in the Global Healthcare Industry
4.3 IVD Applications Face Some Commercial Obstacles
4.4 IVD is the Cornerstone of Personalised Medicine
4.4.1 Personalised Drugs are More Likely to Work Safely and Efficaciously
4.4.2 Advanced Screening for Disease Leading to Quicker Diagnoses
4.4.3 Improved Vaccines
4.4.4 Improvements in Drug Discovery and Reduced Cost of Clinical Trials
4.4.5 European Union IVD Directive (98/79/EC)
4.4.6 Medical Errors Cost the US Billions of Dollars
4.5 Theranostics will Benefit from FDA’s Guidance on Pharmacogenomic Data Submission
4.5.1 Guidance On Pharmacogenomic Data Submission Will Accelerate The Development of Theranostics
4.5.2 Distinguishing Patients at a Greater Risk is Vital
4.5.3 In Future Parallel Use of Markers and Drugs Will Become Prevalent
4.6 Personalised Medicine is a Strong Driver of the IVD Sector
4.6.1 EDMA Cites Theranostics as a Medium-to-Long-Term Driver for Healthcare
4.6.2 Personalised Medicine Constitutes a New Chapter In Diagnostics
4.6.3 The Technology for Personalised Medicine Already Exists
4.7 Identifying Suitable Biomarkers Remains a Significant Challenge
4.8 Theranostics Bill Introduced in the US Senate During 2006
4.9 Development of Novel IVD Products May Be Limited by Low Reimbursement – Will Systems Change Advantageously?
4.10 Cancer Diagnostics is an Important Growth Area With Relevance to In Vitro Diagnostics – Especially Theranostics
4.10.1 Cancer is the Main Developmental Area for Greater Use of In Vitro Diagnostics
4.10.2 Drivers of the Market for IVD and Therapeutics in Oncology
4.10.3 The Oncology Market also has some Restraints
4.11 Collaboration Among Stakeholders is Essential
4.12 Nucleic Acid Testing Technologies Will Be Decisive in the Development of the Theranostics Market
4.12.1 Nucleic Acid Amplification Techniques
4.12.2 Techniques are Presently Complicated
4.12.3 Biochips are Promising
4.12.4 Key Players Large and Small Making Gains in Nucleic Acid Testing
4.12.5 Prospects from Now Looking Forward
4.13 Primary Care and Personal Use of IVD
4.13.1 There is Definitely Scope for Greater Use
4.13.2 What Hurdles Must be Overcome for Point-of-Care IVD Technologies to Become Fully Established in Primary Care?
4.13.3 Personal Use of In Vitro Diagnostic Technologies
4.13.4 While Medical Stakeholders Will Benefit from Molecular Diagnostic and Other Applications of Genomics, Concerns Over Privacy Likely to Impede Progress
4.14 Barriers to the Growth of Pharmacogenomics
4.14.1 Pharmacogenomics Still an Emerging Field
4.14.2 The Complexity of Finding SNP Gene Variations that Affect Drug Responses
4.14.3 Limited Therapeutic Alternatives
4.14.4 Disincentives for Drug Companies to Develop and Produce Multiple Treatments for a Disease
4.14.5 Educating Healthcare Providers
4.15 Potential Changes to Pharma Regulatory and Developmental Processes Dependent upon IVD
4.15.1 Leading Industry Figures Call for More Flexible Approach to Drug Approval
4.15.2 Regulators Acknowledge the Need for Stratification of Treatment Populations
4.15.3 Visiongain Predicts Stratification of Patient Populations Leading to Live-Licensing/In-Life Testing
4.15.4 Stratification of Patients is Key to More Personalised Medicine Sought by Developers and Increasingly Required by Regulators
4.15.5 Traditional Clinical Development has a Significant Disadvantage – Better-Targeted Studies will Take Precedence
4.15.6 Evidence-Based Medicine will Become Increasingly Demanded by Pharma Stakeholders
4.16 Adaptive Clinical Trial Design Will Facilitate Interaction with Regulators and Provide Increased Rationalisation of Drug Development
4.16.1 Adaptive Clinical Trial Design Uses Accumulating Data
4.16.2 Regulators Should be Involved in the Process
4.16.3 Adaptive Trial Design will Gain Acceptance by Early Next Decade
4.17 Personalised Medicine Driven by Theranostics and Live Licensing/In-Life Testing Will Become Established by 2020
4.17.1 Drivers for Better-Targeted Medicine
4.17.2 The Prospects for More-Personalised Medicine and Related Diagnostics are Good
4.17.3 FDA Critical Path Initiative is a Progressive Move in the Right Direction
4.18 Personalised Medicine Aided by Regulatory Reform will also Face Significant Obstacles
4.18.1 The Complex, Disparate Pharma Industry Will Prove Difficult to Reform, Especially in a Revolutionary Manner
4.18.2 It is Unclear How Extensively New Clinical Testing Models and Supporting Regulation will be Applied
4.19 While Personalised Medicine and Better Targeted Clinical Trials are Emerging, Such Developments are Welcomed by the FDA and EMEA
4.19.1 Emerging Developments are Welcomed by Pharma Stakeholders
4.19.2 Cancer Drug Development Leads the Way in its Merging of Drug Development and Treatment of the Disease
4.19.3 FDA's Critical Path Initiative and Personalised Medicine
4.20 Pricing of Personalised Medicine
4.20.1 Personalised Medicine will Lead to Changes in Pricing and Reimbursement
4.20.2 Onus is on Companies to Prove Benefits of their Drugs Including Comparative Cost-Benefits
4.20.3 Biomarkers Can Create Value
4.20.4 The Developments are Complex and Systemic, Posing both Opportunities and Challenges for Healthcare Stakeholders
4.21 The Outlook for In Vitro Diagnostics is Exciting
5 Leading Players and Developments in the IVD Sector
5.1 Profiles of Some Important In Vitro Diagnostics Companies
5.1.1 Roche Diagnostics Division
5.1.2 Abbott Diagnostics
5.1.3 Gen-Probe Inc.
5.1.4 LifeScan Inc.
5.1.5 Axis-Shield
5.1.6 Clinical Data Inc and PGxHealth
5.1.7 Visible Genetics
5.1.8 NGI
5.2 Spotlight on Emerging Companies with High Promise in IVD Technologies
5.2.1 Proteome Sciences – Harnessing Proteomics
5.2.2 Investigen – Novel DNA Testing Applications
5.2.3 DxS Ltd – Facilitating Personalised Medicine
5.2.4 HBV Theranostica – IVD Solutions for Hepatitis B
5.2.5 Enigma Diagnostics - Exciting Developments in Rapid Detection
5.2.6 Itsi-Biosciences – Technology for Proteomics and Biomarker Discovery
5.2.7 Amorfix Life Sciences and Biogen Idec – an Important Partnership
5.2.8 MLT Research Ltd – Technologies Important to IVD
5.2.9 Innogenetics – Ambitious Programme in Theranostics
5.2.10 A&G Pharmaceutical – Solutions for Cancer Theranostics
5.3 Landmark Developments in Theranostics
5.3.1 Genentech’s Herceptin and Novartis’ Gleevec are Probably the Best Known
5.3.2 PharmaNetics’ Thrombolytic Assessment System – Pioneers in the Field
5.3.3 Genentech and DakoCytomation: Herceptin and HercepTest
5.3.4 ImClone Systems and DakoCytomation: Erbitux and EGFR pharmDx Test
5.3.5 Abbott Laboratories’ PathVysion HER-2 DNA Probe Kit
5.3.6 Bayer Diagnostics and Oncogene Science
5.3.7 Novartis and Ventana Medical Systems: Gleevec and VentanaDx c-Kit
5.4 Protein Chip Technologies for Clinical Diagnosis
5.4.1 ProteinChip by Ciphergen
5.4.2 Trinectin Proteome Chip by Phylos
5.4.3 Triage by Biosite
5.4.4 Tissue Microarray Technology
5.4.5 Molecular Diagnostics and Antigen-Antibody Interactions
6 In Vitro Diagnostic Sales in the Leading Developed and Developing Nations, 2007-2023
6.1 Expansion of the World Market Boosted by Increasing Sales in the Developing Healthcare Markets
6.1.1 High Sales in Developed Markets but India and China Catching Up
6.1.2 US to Lead World Market but Leading Developing Markets Exhibiting Highest Growth
6.2 Market Shares of Leading Nations for IVD Sales
6.2.1 US to Lose Market Share to India and China in Particular
6.3 There Will be High Sales Growth in Both Developed and Developing Markets for Diagnostics in the Years Ahead
6.3.1 US is Largest IVD Market
6.3.2 Potential for Sales Growth in Developing Countries is Significant
6.3.3 Improving Access to Modern Healthcare is a Principal Driver of Growth in Developing Nations
6.4 China and India are the Most Exciting New Prospects for the IVD Industry
6.4.1 China and India Both Have the Potential to be Leading Economic Nations
6.4.2 Strategies for Market Entry and Consolidation are Vital for Diagnostics Companies
6.5 WTO Agreements Affect Developments in Emerging Markets
6.5.1 The Principal Diagnostics Markets Remain the Leading Developed Nations But Developing Nations Are Increasingly Important
6.5.2 Expansion into Developing National Markets Will Help to Bring the IVD Industry to a New Level of Commercial Success
7 Theranostics Market Analysis, 2007-2023
7.1 Theranostic Products Will Constitute a Major Driver of the Global IVD Market
7.1.1 IVD Theranostics Market to Expand to Multi-Billion Dollar Sales by 2013
7.1.2 Drive for Personalised Medicine to Boost Theranostic Revenues
7.1.3 Fastest Growth in Cardiovascular & Respiratory and Oncology Segments
7.2 Market Share Gains in Prominent Market Segments
7.2.1 Cardiovascular & Respiratory and Oncology Segments to Gain Market Share from Present Onwards
7.2.2 CNS Segment to Lose Market Share from 2007 Onwards
7.3 Theranostics is Essentially a Fusion of Drug Therapy and Diagnostics
7.3.1 Diagnosis and Treatment Brought Closer Together
7.3.2 Reduction of ADRs
7.3.3 Narrowing of Gap Between Diagnostics and Pharmaceuticals
7.3.4 Recent Advances in Biomedical Sciences Have Made Theranostics Possible
7.3.5 Genentech’s Herceptin is a Prominent Example of the Theranostics Approach
7.3.6 Recent FDA Publication Places Increasing Importance on Theranostics
7.4 Industry Has Been Relatively Slow to Adopt Theranostics - But That Situation Is Changing
7.4.1 Trends in Healthcare are Increasingly Favouring Theranostics
7.4.2 Will The Success of Theranostics Lead To a Shift in Spending From Drugs to Diagnostics?
7.5 Theranostics Will Take Off In a Few Important Therapy Areas First
7.5.1 There are Exciting Possibilities for Theranostics
7.5.2 Cancer Diagnostic Technologies Constitute a Particularly Important Application
7.6 The Improvement in Clinical Performance from Theranostics Will Make It Easier To Justify Costs to Payers
7.6.1 Theranostics Can be a Win-Win for Diagnostics and Pharma Industries
7.6.2 A Theranostic Combination Can Provide an Important Competitive Advantage
7.7 Personalised Medicine Supported By Theranostics Could Supersede the Existing Blockbuster Model, With Sustainable Revenue Flows Continuing
7.7.1 Market is Expanding with Technology Flourishing
7.7.2 The Market for Theranostic Products Is Creating Significant Opportunities for Many Companies in the Pharmaceutical, Diagnostics and Biotechnological Sectors
7.7.3 Rising Health Insurance Coverage Will Benefit the Market
7.7.4 Inter-Industry Links Will Continue to Drive the Theranostics Market
7.7.5 Key Factors Required for Success in the Theranostics Market
8 Interviews with Industry Experts: In Vitro Diagnostics - Current and Future Trends
8.1 Interview 1: Director of a Diagnostics Company
8.1.1 Most Promising Therapeutic areas for IVD
8.1.2 Un-Met Medical Needs in IVD
8.1.3 Greatest Obstacles to Market Growth
8.1.4 Prospects for IVD Market Growth in the Developing Nations
8.1.5 Prospects for Theranostics
8.2 Interview 2: CEO of a Diagnostics Company
8.2.1 Most Promising Therapeutic areas for IVD
8.2.2 Un-Met Medical Needs in IVD
8.2.3 Greatest Obstacles to Market Growth
8.2.4 Prospects for IVD Market Growth in the Developing Nations
8.2.5 Prospects for Theranostics
8.3 Interview 3: Director of a Diagnostics Company
8.3.1 Most Promising Therapeutic areas for IVD
8.3.2 Un-Met Medical Needs in IVD
8.3.3 Greatest Obstacles to Market Growth
8.3.4 Prospects for IVD Market Growth in the Developing Nations
8.3.5 Prospects for Theranostics
8.4 Interview 4: Business Development Director of a Diagnostics Company
8.4.1 Most Promising Therapeutic areas for IVD
8.4.2 Un-Met Medical Needs in IVD
8.4.3 Greatest Obstacles to Market Growth
8.4.4 Prospects for IVD Market Growth in the Developing Nations
8.4.5 Prospects for Theranostics
8.5 Responses from a KOL Survey on Theranostics
8.5.1 How Influential Will Theranostics Be In Coming Years?
8.5.2 Comment on Responses
8.5.3 Are Pharmaceutical and Diagnostic Companies Ready for Closer Links?
8.5.4 Comment on Responses
8.5.5 Will Theranostics Contribute Significantly to Clinical Trials?
8.5.6 Visiongain Comment on Responses
8.5.7 In What Areas Will Theranostics Be Most Prominent?
8.5.8 Visiongain Comment on Responses
9 Conclusions
9.1 In Vitro Diagnostics are Vital to Clinical Decision Making
9.2 Significant Growth of In Vitro Diagnostics Market from 2007 to 2023
9.3 Personalised Medicine Will Rely Heavily Upon Theranostics – Cooperation Between Diagnostics and Pharmaceutical Sectors
9.4 Expansion of the World Market Boosted by Increasing Sales in the Developing Healthcare Markets
9.5 Expansion into Developing National Markets and Lifestyle Diseases Will Drive Market
Appendices
Appendix A: Glossary
Appendix B: Notes on FDA Classification and Regulation of IVD Applications
Appendix C: EC Classification of In Vitro Diagnostic Medical Devices
Appendix D: In Vitro Diagnostics: Prominent Companies
Appendix E: About visiongain
Appendix F: Visiongain report evaluation form
List of Tables
Table 3.1 Sales ($bn) for the World In Vitro Diagnostic Market by Disease Area, 2007-2013
Table 3.2 Sales ($bn) for the World In Vitro Diagnostic Market by Disease Area, 2014-2020
Table 3.3 CAGR (%) for the World In Vitro Diagnostic Market by Disease Area, 2007-2020
Table 3.4 World IVD Market by Disease Area: Long Range Sales Forecasts ($bn) with CAGR (%), 2007-2023
Table 3.5 Market Share (%) for the World In Vitro Diagnostic Market by Disease Area, 2007, 2014, 2018 and 2023
Table 3.6 Sales ($bn) for the World In Vitro Diagnostic Market by Principal Technology, 2007-2013
Table 3.7 Sales ($bn) for the World In Vitro Diagnostic Market by Principal Technology, 2014-2020
Table 3.8 CAGR (%) for the World In Vitro Diagnostic Market by Principal Technology, 2007-2020
Table 3.9 World In Vitro Diagnostic Market by Principal Technology: Long Range Sales Forecasts ($bn) with CAGR (%), 2007-2023
Table 3.10 Market Share (%) for the World In Vitro Diagnostic Market by Principal Technology, 2007, 2014, 2018 and 2023
Table 3.11 Sales ($bn) for the Nucleic Acids Segment of the World IVD Market by Sub Technology, 2007-2013
Table 3.12 Sales ($bn) for the Nucleic Acids Segment of the World IVD Market by Sub Technology, 2014-2020
Table 3.13 CAGR (%) for the Nucleic Acids Segment of the World IVD Market by Sub Technology, 2007-2020
Table 3.14 Nucleic Acids Segment of the World IVD Market by Sub Technology: Long Range Sales Forecasts ($bn) with CAGR (%), 2007-2023
Table 3.15 Market Share (%) for the Nucleic Acids Segment of the World IVD Market by Sub Technology, 2007, 2014, 2018 and 2023
Table 4.1 A SWOT Chart for In Vitro Diagnostic Applications, 2008-2023
Table 4.2 Greater Use of Disease Knowledge and Biomarkers Will Benefit Pharmaceutical Development
Table 6.1 Sales ($bn) for the World In Vitro Diagnostic Market by Leading Nation, 2007-2013
Table 6.2 Sales ($bn) for the World In Vitro Diagnostic Market by Leading Nation, 2014-2020
Table 6.3 CAGR (%) for the World In Vitro Diagnostic Market by Leading Nation, 2007-2020
Table 6.4 World In Vitro Diagnostic Market by Leading Nation: Long Range Sales Forecasts ($bn) with CAGR (%), 2007-2023
Table 6.5 Market Share (%) for the World In Vitro Diagnostic Market by Leading Nation, 2007, 2014, 2018 and 2023
Table 7.1 Sales ($bn) for the World IVD Theranostics Market by Disease Area, 2007-2013
Table 7.2 Sales ($bn) for the World IVD Theranostics Market by Disease Area, 2014-2020
Table 7.3 CAGR (%) for the World IVD Theranostics Market by Disease Area, 2007-2020
Table 7.4 World IVD Theranostics Market by Disease Area: Long Range Sales Forecasts ($bn) with CAGR (%), 2007-2023
Table 7.5 World IVD Theranostics Market Sales Compared With Overall IVD Market ($bn), Market Share (%) and CAGR (%), 2007-2023
Table 7.6 Market Share (%) for the World IVD Theranostics Market by Disease Area, 2007, 2014, 2018 and 2023
Companies Listed
3M
A&G Pharmaceutical
Abbott Diagnostics
Abbott Laboratories
Affymetrix
Agendia
Agilent Technologies Inc.
American Diagnostica
Amorfix Life Sciences
Applera Corporation
Applied Biosystems
Applied Imaging
Apria Healthcare
Arcturus
ARKRAY Incorporated
AstraZeneca
Athena Diagnostics
Axis-Shield
Baxter International Inc.
Bayer
Bayer Diagnostics
Beckman Coulter
Becton Dickinson
Binax Incorporated
Biogen Idec
BioMerieux
Bio-Rad Laboratories Incorporated
Biosite
Bristol-Myers Squibb
Cambridge Theranostics
CanAg Diagnostics
Celera Diagnostics, see Applera Corporation
Chiron
Ciphergen Biosystems
Clarient
Clinical Data Inc.
Competitive Technologies
CyGene
Cytyc
Dade Behring
DakoCytomation
Del Mar Reynolds Medical Ltd.
Diagnostic Products Corporation
Diagnostic Systems Laboratories
Digene Corporation
DNAPrint Genomics
DxS Ltd
Enigma Diagnostics Ltd
Epigenomics
EXACT Sciences
First Check Diagnostics
Fisher Scientific
Fornix Theranostics
Fresenius Medical Care
Fujirebio Diagnostics
Gambro AB
GE Healthcare
Gemini (Eurona)
Genaissance Pharmaceuticals
Genentech
GeneOhm Sciences
General Nutrition Centers Inc.
Genetic Vectors
Gen-Probe Inc.
Gentiva Health Services Inc.
Genzyme
Glaxo Wellcome
Graham-Field Health Products
HBV Theranostica
Health Discovery
HealthGrades
Hypoguard USA
Hyseq
IGEN International
ImClone Systems
Innogenetics
Intronn Inc.
Invacare Corporation
Inverness Medical Innovations
Investigen
Invitrogen Corporation
Itsi-Biosciences
Johnson & Johnson
Kingo Diagnostika
LabCorp
Lifescan Inc.
Lincare
Lpath Therapeutics
Lumigen
Matria Healthcare
MDY Healthcare plc
Medisys plc
Merck & Co.
Merck KGaA
Millennium Predictive Medicine
MLT Research Ltd
Monogram Biosciences
Myriad Genetics Inc.
Neighborhood Connections
NGI
Nova Biomedical Corporation
Novartis
Olympus Corporation
Oncogene Sciences
Oncomethylome Sciences
Organon Teknika
Orion Genomics
Ortho-Clinical Diagnostics
Pathwork Informatics
PeptiFarma
PerkinElmer Incorporated
PGxHealth
PharmaNetics
Phylos
Power3 Medical
Primagen
Primus Corporation
Pronto Diagnostics
Proteome Sciences
Provalis
QIAGEN NV
Quest Diagnostics
Quidel
Ranbaxy Laboratories
Respironics
Response Biomedical
Roche
Rubicon Genomics
Seapro Theranostics International B.V
Sequenom
Siemens Medical Solutions
Sunrise Medical
TheraNostics GmbH
Thermo Electron
Tibotec-Virco
Trinity Biotech plc
TriPath Imaging Inc.
Ventana Medical Systems
Veridex LLC
Veri-Q Inc.
Visible Genetics
Vysis Inc.
Wyeth
[Fade out table of contents]
